Anatara takes next step in testing its answer to US$8 billion global IBS issue
Anatara Lifesciences (ASX:ANR) has met the projected milestone to finalise a draft protocol for a human clinical trial for its GaRP dietary supplement in the treatment of irritable bowel syndrome (IBS).
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed